Section Arrow
VOGX.NASDAQ
- Vogenx Inc
Quotes are at least 15-min delayed:2026/08/17 16:45 EDT
After Hours
Last
 16.57
+0.82 (+5.21%)
Bid
16.57
Ask
23.64
High 16.57 
Low 15.75 
Volume 994 
Regular Hours (Closed)
Last
 15.75
+0.97 (+6.56%)
Day High 
16.3 
Prev. Close
14.78 
1-M High
16.65 
Volume 
31.47K 
Bid
16.57
Ask
23.64
Day Low
14.8 
Open
15.002 
1-M Low
12.95 
Market Cap 
205.53M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA -- 
20-SMA -- 
50-SMA -- 
52-W High 16.65 
52-W Low 12.95 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.20/--
Enterprise Value
205.53M
Balance Sheet
Book Value Per Share
-0.10
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
--
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OSRHOSR Health Inc0.59+0.274+86.71%10.53PE
After Hours 0.604 +0.014 +2.37%
OTLKOutlook Therapeutics0.6722-0.0842-11.13%-- 
After Hours 0.6778 +0.0056 +0.83%
EYPTEyePoint Inc.4.87-9.88-66.98%-- 
After Hours 4.82 -0.05 -1.03%
VBIOValion Bio Inc.0.1825-0.0081-4.25%-- 
After Hours 0.18 -0.0025 -1.37%
GOSSGossamer Bio0.14-0.0142-9.21%-- 
After Hours 0.1433 +0.0033 +2.36%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.